Search clinical trials for: CKD-381(formulation II)

Total 261 results

GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
Chinese Academy of Medical Sciences, Fuwai Hospital
National Natural Science Foundation of China

Recruiting

Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention

Hypertension

China
Marinus Pharmaceuticals

Completed

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 (0602)

Epilepsy, Complex Partial

United States
Nabriva Therapeutics AG

Completed

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia (LEAP2)

Community Acquired Pneumonia

United States, Argentina, Brazil, Bulgaria, Chile, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, South Africa, Spain, Taiwan, Ukraine
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
University Hospital, Geneva
World Health Organization; AIC Kijabe Hospital

Completed

Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation

Postoperative Wound Infection

Kenya
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditions

United States
Sohag University

Recruiting

Type VI Secretion System in Klebsiella Pneumoniae (Klebsiella)

Detection of Type VI Secretion System in K.Pneumoniae | Detection of Relation to Ab Resistance, Biofilm

Egypt
National Cancer Institute (NCI)

Completed

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

B-Cell Lymphoma

United States
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B

Hypertension
Chong Kun Dang Pharmaceutical

Completed

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

CKD-828 (80/5mg) Pharmacokinetic Study (CKD-828)

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

CKD-828 (80/5mg) Pharmacokinetic Study

Hypertension

Korea, Republic of
Aciex Therapeutics, Inc.

Completed

A Comparison of the Safety and Comfort of AC-170

Normal Ocular Health

United States
University of Ulm
Jazz Pharmaceuticals

Recruiting

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Acute Myeloid Leukemia

Austria, Germany
Nabriva Therapeutics AG

Completed

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia (LEAP)

Community Acquired Pneumonia

United States, Argentina, Bosnia and Herzegovina, Brazil, Bulgaria, Georgia, Hungary, Latvia, Netherlands, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, South Africa, Thailand, Ukraine
Jazz Pharmaceuticals

Completed

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Acute Myeloid Leukemia

United States, Canada
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent Disease

United States
M.D. Anderson Cancer Center

Completed

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Solid Tumors

United States
Ohio State University Comprehensive Cancer Center
Incyte Corporation; Jazz Pharmaceuticals

Recruiting

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Secondary Acute Myeloid Leukemia | Myeloproliferative Neoplasm

United States
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

Hypertension

Korea, Republic of
University of Texas Southwestern Medical Center
Gateway for Cancer Research; Celldex Therapeutics

Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Metastatic Breast Cancer | HER2-negative Breast Cancer

United States
M.D. Anderson Cancer Center

Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations

United States
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

Hypertension
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
Roswell Park Cancer Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

Recurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Salivary Gland Cancer | Stage IV Adenoid Cystic Carcinoma of the Oral Cavity | Stage IV Salivary Gland Cancer | Salivary Gland Adenoid Cystic...

United States
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Completed

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia | Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Completed

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
GWT-TUD GmbH

Recruiting

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA)

AML | MDS

Germany, Austria
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
Jazz Pharmaceuticals

Completed

Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Hematologic Neoplasms

United States
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, Taiwan, United Kingdom, Germany, Spain, Israel, Romania, South Africa, Korea, Republic of, Australia, Canada, Hungary, Ireland, Latvia
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia | Adult Acute Lymphoblastic Leukemia

United States
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Acute Myeloid Leukemia

China
Children's Hospital Medical Center, Cincinnati

Recruiting

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
Sanofi

Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Terminated

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Refractory Multiple Myeloma

United States
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

High Risk Acute Myeloid Leukemia

United States, Canada
University of California, Irvine
Pfizer; Jazz Pharmaceuticals

Recruiting

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Acute Myelogenous Leukemia (AML) Due to Therapy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

United States
Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Small Cell Lung Carcinoma

United States, Poland, Israel, Argentina, Australia, Austria, Canada, China, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, Portugal, Romania, Spain, Turkey, United...
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects

Healthy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment (ERASE)

Leukemia, Myeloid, Acute

Search clinical trials for: CKD-381(formulation II)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations